Key Takeaways:A clinical trial presented at ATS 2025 found high patient adherence to Viatom’s ring pulse oximeter for monitoring OSA over multiple nights. Researchers reported that longitudinal data helped assess night-to-night variability and treatment response in OSA patients. The ATS abstract, funded by Apnimed Inc, reports that Viatom’s ring pulse oximeter had high rates of utilization by patients. Worn as a ring, Viatom’s O2 Ring uses transmittance-based photoplethysmography and engages in continuous data collection, rather than spot checks. The connected software has not been submitted to the FDA for marketing approval, so it cannot be deployed outside of clinical trial settings.